Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We believe this technology is ideally suited to treat autoimmune conditions with high unmet medical need and significant commercial opportunities and our preclinical work in multiple sclerosis, and inflammatory bowel disease supports that potential |
| Sangamo has a long impressive, history of scientific innovation, leading to new discoveries and industry first for genomic medicines |
| Your tireless efforts and dedication have helped to progress Sangamo’s science and support the organization and for that I am very grateful and I wish you the very best in your next chapters |
| The favorable safety profile comes from the specificity we're able to achieve coupled with the fact that Zinc Fingers are human-derived reducing issues related to immunogenicity |
| As I look to the future, I am excited to the opportunities that lie ahead |
| The promising preclinical evidence from our Zinc Finger editing capabilities, coupled with the strong progress we're making to identify novel capsids with enhanced delivery capabilities demonstrates the potential for Sangamo to become a leader in this space |
| Our differentiated combination of precise, versatile, and compact genome targeting cargo, alongside our novel AAV capsid evolution engine, which has the potential for meaningfully improved central nervous system construction efficiency forms the foundation from which we believe we can transform the lives of patients with neuro generative diseases such as intractable pain conditions, prion disease, Alzheimer's and many other neurological conditions |
| And as such, we're pleased to see that Zinc Fingers are increasingly being recognized in the fields for these benefits and being more widely embraced |
| So we're very encouraged and we have regular call with our Pfizer colleague and the momentum is palpable |
| We believe this provides a strong foundation for the future of Sangamo given our unique position and ability to lead in the area of epigenetic regulation |
| This gives us both the competitive advantage as we progress our neurology pipeline and presents future opportunities for partnerships |
| We're unique in the company, really that is why I'm so excited about this work, because we have the outstanding Zinc Finger platform, but also, this capsid delivery effort that will allow us to create the medicines that I talked about before that are really bringing together those components |
| Sangamo has highly differentiated technology that we believe allows us to execute on our strategy |
| We have received testimonies from patients seeing that the impact of ST-920 has been transformative and to report real and meaningful improvements in the quality of life, some even over and above the benefits that they were experiencing on ERT |
| At a high level, we have a differentiated platform that can create powerful genomic medicine that’s part of our genome targeting cargo, the preclinical data that demonstrates the potency, specificity and importantly, the efficacy we may be able to achieve |
| We're confident in the hands of a partner ST-920 will make an enormous difference to the Fabry community |
| The neurology-focused genomic engineering business is the future of Sangamo and is a combination of our strategy that has been in the works for some time because of the compelling focused business model it represents and the potential commercial opportunities we believe it affords, we are excited about the opportunities that lie ahead, opportunities are best for patients, best for advancing our science and best for the shareholders who have stayed with us through this journey |
| We are proud of our efforts to advance innovation in the CAR-Treg field |
| Sangamon has both the differentiated genome-targeted cargo and the delivery capabilities of the capsid to be positioned favorably versus others in the field |
| We also received RMAT designation recently from the USFDA which really is a recognition that this potential medicine address significant unmet needs for Fabry patient population, but also a signal that the data produced so far has been highly encouraging |
| The product candidate continues to be well tolerated for all treated patients today and we're encouraged by the early translational medicine data emerging from this study |
| So we're very pleased that we are - will be in a very good position for any potential partner to start our Phase 3 program |
| So we are very excited about this and it also demonstrates our manufacture capability for the T-Reg platform |
| We believe that the approach we are using the Zinc Fingers, it gives us a really unprecedented opportunity to regulate gene expression in the brain and match it specifically to the neurological disease indications being able to precisely and specifically up regulated or down regulated genes that are involved in these really challenging neurological diseases gives a new opportunity to treat those diseases |
| In defining our pipeline and pathway forward, we choose to focus on indications where there is a clear driver of disease, not only do we believe the strengthening the likelihood of pre-clinical success, but we also believe it increases the speed to potential approval, because the drivers of disease are well understood meaning we know which genes cause the diseases, we're able to effectively target those genes that offer curative potential pursuing the fundamental drivers of disease within our view of very compelling approach |
| All the progress being made in the clinical program is exciting the real value of this business is in what lies beyond the proof-of-concept with Tx-200 |
| I am so honored to lead a company with such deep scientific expertise and a team so dedicated to their mission of transforming patients' life with our technology |
| As we have shared before, we strongly believe our technology is ideally suited to address a range of devastating neurological indications that are few if any treatment options available today |
| I strongly believe that our Fabry disease program is potentially transformative for patients |
| We have shown and strongly believe in the promise of ST-920 as a potential medicine for patients suffering with Fabry disease |
| Statement |
|---|
| The public biotech markets have been challenging for over two years now and we find ourselves in a similar position to many of our peers with limited capital resources and a tough path to navigate ahead |
| I think we're not successful in closing collaboration or financing transaction over the coming months |
| It's an immensely difficult decision to de-prioritize spending on our legacy clinical programs, which have such clinical promise |
| The difficulties in accessing capital being experienced across the industry have accelerated the pace of our plans |
| Over the course of 2023, we have proactively made difficult decisions to preserve our most valuable assets |
| While our programs are delivering promising results, the environment within which we are operating has been and is slightly to remain challenging |
| The cost of progressing the program beyond the current Phase 1/2 study would constrain our resources and require significant development and commercial investments which we do not have the ability to support at this time |
| You'll hear us say throughout this, it's capsids and cargo, you have to have capsid and cargo to be successful |
Please consider a small donation if you think this website provides you with relevant information